JP2022501428A - 抗ｌｉｌｒｂ２抗体およびその使用の方法 - Google Patents

抗ｌｉｌｒｂ２抗体およびその使用の方法 Download PDF

Info

Publication number
JP2022501428A
JP2022501428A JP2021539483A JP2021539483A JP2022501428A JP 2022501428 A JP2022501428 A JP 2022501428A JP 2021539483 A JP2021539483 A JP 2021539483A JP 2021539483 A JP2021539483 A JP 2021539483A JP 2022501428 A JP2022501428 A JP 2022501428A
Authority
JP
Japan
Prior art keywords
seq
amino acid
set forth
acid sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539483A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020061059A5 (https=
JP2022501428A5 (https=
Inventor
チェン，シュ−シャー
パン，ピン−イン
Original Assignee
アイカーン スクール オブ メディスン アット マウント シナイ
ザ メソディスト ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディスン アット マウント シナイ, ザ メソディスト ホスピタル filed Critical アイカーン スクール オブ メディスン アット マウント シナイ
Publication of JP2022501428A publication Critical patent/JP2022501428A/ja
Publication of JPWO2020061059A5 publication Critical patent/JPWO2020061059A5/ja
Publication of JP2022501428A5 publication Critical patent/JP2022501428A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021539483A 2018-09-17 2019-09-17 抗ｌｉｌｒｂ２抗体およびその使用の方法 Pending JP2022501428A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732299P 2018-09-17 2018-09-17
US201862732334P 2018-09-17 2018-09-17
US62/732,299 2018-09-17
US62/732,334 2018-09-17
PCT/US2019/051529 WO2020061059A1 (en) 2018-09-17 2019-09-17 Anti-lilrb2 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022501428A true JP2022501428A (ja) 2022-01-06
JPWO2020061059A5 JPWO2020061059A5 (https=) 2022-09-29
JP2022501428A5 JP2022501428A5 (https=) 2022-09-29

Family

ID=69888746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539483A Pending JP2022501428A (ja) 2018-09-17 2019-09-17 抗ｌｉｌｒｂ２抗体およびその使用の方法

Country Status (8)

Country Link
US (1) US12157768B2 (https=)
EP (1) EP3852805A4 (https=)
JP (1) JP2022501428A (https=)
KR (1) KR20210108940A (https=)
CN (1) CN113543804A (https=)
AU (1) AU2019343131A1 (https=)
CA (1) CA3111862A1 (https=)
WO (1) WO2020061059A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428604A (zh) 2018-07-09 2024-07-16 美商戊瑞治療有限公司 結合至ilt4的抗體
WO2021126906A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
MX2023003186A (es) * 2020-09-17 2023-04-13 Merck Sharp & Dohme Llc Regimenes de dosificacion de anticuerpo anti-ilt4 o su combinacion con anticuerpo anti-pd-1 para el tratamiento de cancer.
EP3981789A1 (en) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb antibodies and uses thereof
EP4232087A4 (en) * 2020-10-21 2024-10-09 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS
CN117321083A (zh) * 2021-03-11 2023-12-29 大学保健网 Lilrb1和lilrb2结合分子及其用途
CA3225139A1 (en) * 2021-07-01 2023-01-05 Albert Einstein College Of Medicine Compositions and methods for inhibiting the expression of tmigd2
CN119213023A (zh) * 2022-03-29 2024-12-27 恩格姆生物制药公司 Ilt3和cd3结合剂以及其使用方法
WO2023235706A1 (en) * 2022-05-31 2023-12-07 Ngm Biopharmaceuticals, Inc. Combination therapies using ilt-binding agents and pd-1 inhibitors
CN116333128B (zh) * 2022-06-28 2026-03-24 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN116082504A (zh) * 2022-06-28 2023-05-09 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN119604531A (zh) * 2022-07-29 2025-03-11 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
WO2024041315A1 (en) * 2022-08-22 2024-02-29 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-lilrb2 antibodies and uses thereof
JP2025532504A (ja) * 2022-09-08 2025-10-01 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｉｌｔ４抗体及びその医薬的使用
KR20250090398A (ko) * 2022-09-28 2025-06-19 스팍스 바이오사이언스 리미티드 백혈구 면역글로불린 유사 수용체 하위 패밀리 b 구성원 2(lilrb2)에 결합하는 항체 및 그 용도
CN120548326A (zh) * 2022-12-23 2025-08-26 艾奥麦克斯治疗公司 靶向白细胞免疫球蛋白样受体亚家族b1（lilrb1）和lilrb2的交叉特异性抗原结合蛋白（abp）、其组合和用途
EP4491230A1 (en) * 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
JP2026504928A (ja) * 2023-01-20 2026-02-10 ワシントン・ユニバーシティ Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法
CN116789826A (zh) * 2023-05-12 2023-09-22 南京师范大学 抗人lilrb2全人源单域抗体及其应用
CN119176874A (zh) * 2023-06-21 2024-12-24 康源博创生物科技(北京)有限公司 一种能够结合lilrb2的抗体或其抗原结合片段
WO2025128822A1 (en) * 2023-12-12 2025-06-19 The Methodist Hospital Lilrb3 modulators and methods of use thereof
GB202319149D0 (en) * 2023-12-14 2024-01-31 Kbio Holdings Ltd Antibody
CN121299117B (zh) * 2025-12-05 2026-03-27 中国农业科学院都市农业研究所 检测猪轮状病毒的试剂和纳米酶免疫层析试纸条及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510340A (ja) * 2015-03-06 2018-04-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
WO2018091661A1 (en) * 2016-11-18 2018-05-24 Symphogen A/S Anti-pd-1 antibodies and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014064287A1 (en) * 2012-10-26 2014-05-01 Deutsches Rheuma-Forschungszentrum Berlin Bi-specific affinity reagents for cell-lineage-specific tnf-alpha neutralisation
US9429584B2 (en) * 2013-02-28 2016-08-30 National Cancer Center Antibody against insoluble fibrin
US10138286B2 (en) 2013-03-12 2018-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
KR20170007449A (ko) * 2014-05-22 2017-01-18 프레드 헛친슨 켄서 리서치 센터 조혈 전구체 세포의 lilrb2 및 노치 매개 증식
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510340A (ja) * 2015-03-06 2018-04-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
WO2018091661A1 (en) * 2016-11-18 2018-05-24 Symphogen A/S Anti-pd-1 antibodies and compositions

Also Published As

Publication number Publication date
US20220056128A1 (en) 2022-02-24
AU2019343131A1 (en) 2021-04-29
EP3852805A1 (en) 2021-07-28
CN113543804A (zh) 2021-10-22
EP3852805A4 (en) 2022-06-15
KR20210108940A (ko) 2021-09-03
WO2020061059A1 (en) 2020-03-26
CA3111862A1 (en) 2020-03-26
US12157768B2 (en) 2024-12-03

Similar Documents

Publication Publication Date Title
US12157768B2 (en) Anti-LILRB2 antibodies and methods of use thereof
JP7728822B2 (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
US20240076375A1 (en) Anti-TIM-3 Antibodies and Use Thereof
JP2022065073A (ja) Ｂｃｍａ結合分子及びその使用方法
US10604576B2 (en) Antibodies and immunocytokines
JP7034934B2 (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
JP2022028750A (ja) Ｃｄ１９に対するヒト化抗原結合ドメイン及び使用方法
US11787858B2 (en) Anti-LILRB3 antibodies and methods of use thereof
KR20200105849A (ko) 항-tigit 항체 및 치료제 및 진단제로서 이의 용도
CN107949571A (zh) 调控免疫反应的方法及抗体
CN110856446A (zh) 抗pd-l1抗体及其用途
CN113004408B (zh) 抗人程序死亡因子-1单克隆抗体
JP2023519644A (ja) Ｓｓｅａ－４結合メンバー
JP2025506143A (ja) 多重特異性結合性作用剤およびその使用
CN121816190A (zh) 双靶标car-t细胞在治疗b细胞自身免疫性疾病中的用途
EP4568998A1 (en) B7-h3 antigen-binding molecules
TWI917318B (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑
KR20260052102A (ko) B 세포 자가면역 질환 치료에서 이중 표적 car-t 세포의 용도
HK40097160A (zh) 抗tim-3抗体及其用途
HK40088438A (zh) 抗tim-3抗体及其用途
HK40061606B (zh) 嵌合抗原和t细胞受体及使用的方法
TW202045547A (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240514